



Calbiochem®

# Biologics

PI 3-Kinase:  
A Multifunctional  
Signaling Molecule

Volume 33, No. 2, 2007

## Inside this issue...

PI 3-Kinase: A Multifunctional Signaling Molecule .....	3
Inhibitors for PI 3-Kinase/ Akt Signaling Pathway .....	5
<b>NEW</b> Recombinant PI 3-Kinases .....	6
Antibodies for PI 3-Kinase Research .....	7
<b>NEW</b> Apoptosis Research Products .....	7
The IKK-NF- $\kappa$ B System: A Target for Inflammation and Cancer .....	10
<b>NEW</b> Inhibitors of NF- $\kappa$ B Activation Scheme .....	11
Antibodies for NF- $\kappa$ B Activation Research .....	11
<b>NEW</b> Protein Kinase Inhibitors .....	12
<b>NEW</b> Aurora A and K-LISA™ Aurora Kinase Activity Kit .....	14
<b>NEW</b> Recombinant Protein Kinases .....	14
<b>NEW</b> Inhibitors for Angiogenesis Research .....	15
Proteins for Angiogenesis Research .....	16
<b>NEW</b> Research Tools for Diabetes Research .....	17
Stem Cell Marker Antibodies .....	19
Modulators of Stem Cell Differentiation .....	20
<b>NEW</b> Kits for Proteomics Research .....	20
<b>NEW</b> Histone Deacetylase Inhibitors .....	22



Calbiochem®

The **InhibitorSelect™ Protein Kinase Inhibitor Library** includes 80 well-characterized protein kinase inhibitors on a single 96-well plate. The library includes inhibitors against a panel of structurally diverse protein kinases.

Suitable for:

- ✓ Target validation
- ✓ Pathway analysis
- ✓ Assay development
- ✓ Kinase screening

**Targets:** Akt; AMPK; Aurora; DNA-PK; IRAK; PKC; Rho; TGF-βR; Bcr-Abl; EGFR; FLT3; FMS; IGFR; JAK; Lck; Met; PDGFR; Src; Syk; VEGFR; and PI 3-K

Visit our website  
for more information:

[www.calbiochem.com/  
inhibitorkinaselibrary](http://www.calbiochem.com/inhibitorkinaselibrary)

# Protein Kinase Inhibitor Library

Cat. No. 539744




Plate Features	Inhibitor Features	Documentation
96-well format	Convenient, ready-to-use	Structure SD-files
10 mM DMSO solution	Cell-permeable	Published IC <sub>50</sub> values
50 µl/well	Majority are ATP-competitive	CAS numbers
Polypropylene plate	Stable in DMSO	Literature citations
Tight robust silicone seal	Structurally most diverse selection	PubChem ID
Non-pyrogenic	Multiple inhibitors against selected targets	Inhibitor description

All inhibitor solutions have ≥95% purity (HPLC). Lot specific data for every inhibitor in solution is available.

# Phosphoinositide 3-Kinase (PI 3-K):

## A Multifunctional Signaling Molecule


Chandra Mohan, Ph.D., EMD Chemicals, San Diego, California 92121

The PI 3-kinases are ubiquitous enzymes that play a crucial role in the regulation of many cellular processes, including cell growth, proliferation, motility, and survival. The PI 3-kinase family constitutes a large family of lipid and serine/threonine kinases, which includes a number of phosphatidylinositol kinases, as well as the ATM and ATR kinases. PI 3-kinases are divided into three classes based on their structure and substrate specificity. Class I PI 3-kinases, the best studied class, were the first to be characterized and include receptor-regulated heterodimeric enzymes, which contain a 110 kDa catalytic subunit and an 85 kDa regulatory subunit. The class IA PI 3-kinases (p110 $\alpha$ , p110 $\beta$  and p110 $\delta$  isozymes) associate with an 85 kDa adapter/regulatory subunit that is essential for interaction of these PI 3-kinases with receptor tyrosine kinases and intracellular proteins, such as PKC, SHP1, Rac, and Rho. The class IB PI 3-kinases (p110 $\gamma$ ) are activated by heterotrimeric G protein  $\beta\gamma$ -subunits and associate with a p101 adapter/regulatory subunit that is important for full responsiveness to  $G_{\beta\gamma}$  heterodimers. PI 3-kinases of both class IA and IB are also activated by Ras. They can use PI, PI (4)P and PI (4,5)P<sub>2</sub> as substrates *in vitro*. Their major *in vivo* substrate appears to be PI(4,5)P<sub>2</sub>. The members of this class are sensitive to wortmannin. Class II PI 3-kinases are larger monomeric enzymes (~170 kDa) and show variable responses to wortmannin. They lack the adapter/regulatory subunit and use PI and PI(4)P as substrates. This class of enzymes contains a C-2 domain at the C-terminal region that binds phospholipids in a Ca<sup>2+</sup>-dependent manner. They are known to participate in integrin signaling in platelets. Three isoforms of class II PI 3-kinases have been described in mammals: the ubiquitously expressed PI 3-kinase C2 $\alpha$  and PI 3-kinase C2 $\beta$ , and a liver-specific PI 3-kinase C2 $\gamma$ . PI 3-kinases of class III are heterodimeric enzymes consisting of an adaptor unit, p150 and catalytic subunit Vps34 of 100 kDa size, which can phosphorylate PI(3)P. The human homolog of Vps34 is reported to be sensitive to wortmannin and participates in the regulation of endocytic membrane trafficking and in the regulation of autophagy.

Following ligand binding to receptor and activation of receptor tyrosine kinase, the p85/p110 complex is recruited to the receptor by interaction of the SH2 domain of p85 with consensus phosphotyrosine residues on receptor tyrosine kinase. This allows the p110 catalytic subunit to come in close proximity to its lipid substrates in the cell membrane. The interaction of a receptor tyrosine kinase with the p85 subunit relieves the inhibitory effect of p85 on the p110 catalytic subunit. Activated PI 3-kinase phosphorylates phosphoinositol (PI) substrates to produce PI(3)P, PI(3,4)P<sub>2</sub>, and PI(3,4,5)P<sub>3</sub> (PIP<sub>3</sub>). These molecules act as second messengers and recruit the PI 3-kinase-dependent serine/threonine kinases (PDK1) and Akt from the cytoplasm to the plasma membrane. Lipid binding and membrane translocation of Akt leads to conformational changes, which allow it to become phosphorylated on Thr<sup>308</sup> in the activation loop and Ser<sup>473</sup> in the hydrophobic phosphorylation motif by PDK1 and PDK2. This dual phosphorylation causes full activation of Akt. ►►







The PI 3-kinase pathway diverges at many points in the metabolic scheme, resulting in a variety of physiological effects. PI 3-kinase activation of Akt and subsequent activation of mTOR stimulates cell proliferation and the translation process in response to nutrients and growth factors. It phosphorylates p70S6 kinase and 4E-binding protein (4E-BP). Phosphorylation of 4E-BP allows the release of translation initiation factor, eIF4E. The PI 3-kinase/Akt pathway is also involved in the LKB1-mediated activation of AMP-activated protein kinase (AMPK) that inhibits mTOR activity, thereby allowing energy conservation in the cell. Akt also phosphorylates p21<sup>WAF1</sup> and p27<sup>KIP1</sup>, allowing them to be exported to the cytoplasm for sequestration and degradation. This allows cell proliferation to proceed unimpeded. Several other proteins have also been identified as intracellular targets of PI 3-kinase/Akt.

Class IA PI 3-kinase signaling is considered to be important in mediating insulin responses in cells. Any loss in the activity of these kinases can result in metabolic defects linked to type 2 diabetes. Inhibition of PI 3-kinase and overexpression of dominant negative PI 3-kinase mutants are shown to block many of the physiological responses to insulin. Pharmacological inhibition of PI 3-kinase by

wortmannin or LY294002 is shown to diminish insulin-stimulated translocation of GLUT4 to the cell surface and reduce glucose uptake into cells. Overexpression of constitutively active forms of PI 3-kinase p110 catalytic subunit stimulates insulin-mediated metabolic effects and dominant-negative p85 regulatory subunit constructs block insulin-mediated metabolic effects. Akt2, a downstream target of PI 3-kinase, is highly expressed in insulin-responsive tissues, such as muscle and adipose tissue, and is essential for the maintenance of glucose homeostasis. Mice deficient in Akt2 display classical features of type 2 diabetes.

Under resting conditions, PIP<sub>3</sub> levels are practically undetectable in mammalian cells. Levels of PIP<sub>3</sub> are controlled tightly by the action of several PIP<sub>3</sub> phosphatases, such as PTEN, SHIP1, and SHIP2. PTEN acts on the 3-position to convert PIP<sub>3</sub> back to PI(4,5)P<sub>2</sub> (PIP<sub>2</sub>). On the other hand, the SHIP phosphatases remove phosphate from the 5-position to produce PI(3,4)P<sub>2</sub>. PIP<sub>2</sub> can also function as a second messenger to recruit PH-domain-containing proteins, such as Akt. Overexpression of PTEN is sufficient to lower basal levels of 3'-phosphorylated phosphoinositide in cells. PTEN<sup>-/-</sup> mice exhibit higher levels of 3'-phosphorylated phospholipids and die during embryogenesis due to the

## Phosphoinositide 3-Kinase (PI 3-K) (continued...)

failure of developmental apoptosis. PTEN<sup>-/-</sup> mouse embryo fibroblasts are shown to be resistant to apoptotic stimuli. Deletion of SHIP also leads to an increase in PIP<sub>3</sub> levels and a decrease in PIP<sub>2</sub> levels. SHIP<sup>-/-</sup> mice are also shown to have defective apoptotic machinery and excessive cell survival in the myeloid lineages.

PI 3-kinase signaling is crucial to many aspects of cell growth and survival and this pathway is stimulated by many growth factors. Hence, PI 3-kinase activity is tightly regulated in normal cells. Overactivation of this pathway can perturb the control mechanisms for cell growth and survival and contribute to metastatic competence and resistance to chemotherapy. Abnormal activation of PI 3-kinases is seen in several forms of cancer. About 30% of solid tumors contain mutations in the catalytic unit of their PI 3-kinase, which increases its enzymatic activity and produces excessive Akt signaling. Somatic missense mutations in the p110 $\alpha$  gene are reported in HER2-amplified and hormone-receptor-positive breast cancers. Also, p110 $\alpha$  is frequently overexpressed and mutated in gliomas, colon, prostate, and gynecological tumors. Several tumors also exhibit either defective or diminished activity in the tumor suppressor, PTEN. Deletion of PTEN in T cells or B cells is shown to enhance their proliferation. Mice heterozygous

for PTEN show a predisposition for developing leukemia and lymphoma. Additionally, PI 3-kinase inhibitors, wortmannin and LY294002 exhibit antitumor activities and sensitize tumor cells to chemotherapeutic agents. Given the importance of the PI 3-kinase signaling pathway, several new drug candidates are being sought. A few isoform-selective inhibitors have also been identified. Stable, water-soluble conjugates of wortmannin are being developed to improve its pharmacological characteristics. ■

### References:

- Ito, K., et al. 2007. *J. Pharmacol. Exp. Ther.* 321, 1.  
Medina-Tato, D.A., et al. 2007. *Immunology* 121, 448.  
Leslie, N.R. 2006. *Antioxid. Redox Signal.* 8, 1765.  
Workman, P., et al. 2006. *Nat. Biotech.* 24, 794.  
Samuels, Y., and Ericson, K. 2006. *Curr. Opin. Oncol.* 18, 77.  
Bader, A.G., et al. 2005. *Nat. Rev. Cancer* 5, 921.  
Hennessy, B.T., et al. 2005. *Nat. Drug Disc.* 4, 988.  
Fruman, D.A. 2004. *Biochem. Soc. Trans.* 32, 315.  
Scheid, M.P., and Woodgett, J.R. 2003. *FEBS Lett.* 546, 108.  
Lawlor, M.A., and Alessi, D.R. 2001. *J. Cell Sci.* 114, 2903.  
Toker, A., and Newton, A.C. 2000. *J. Biol. Chem.* 275, 8271.  
Stein, R.C., and Waterfield, M.D. 2000. *Mol. Med. Today* 6, 347.  
Datta, S.R., et al. 1999. *Genes Dev.* 13, 2905.  
Dong, Z., et al. 1999. *Anticancer Res.* 19, 3743.  
Prior, I.A., and Clague, M.J. 1999. *Mol. Cell Biol. Res. Commun.* 1, 162.  
Shepherd, P.R., et al. 1996. *J. Mol. Endocrinol.* 17, 175.


## **NEW** Inhibitors for PI 3-Kinase/Akt Signaling Pathway

### PI-103

(3-(4-(4-Morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol)

A cell-permeable potent and ATP-competitive inhibitor of DNA-PK, PI 3-K, and mTOR (IC<sub>50</sub> = 2, 8, 88, 48, 150, 26, 20, and 83 nM for DNA-PK, p110 $\alpha$ , p110 $\beta$ , p110 $\delta$ , p110 $\gamma$ , PI 3-KC2 $\beta$ , mTORC1, and mTORC2, respectively).

Purity:  $\geq 97\%$  by HPLC. M.W. 348.4



Cat. No. 528100

1 mg  
5 mg


€89  
€324

Ref.: Raynaud, F.I., et al. 2007. *Cancer Res.* 67, 5840; Fan, Q.W., et al. 2006. *Cancer Cell* 9, 341; Knight, Z.A., et al. 2006. *Cell* 125, 733.

### PDK1/Akt/Flt Dual Pathway Inhibitor

(6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one & 10H-Indeno[2,1-e]tetrazolo[1,5-b][1,2,4]triazin-10-one)

A cell-permeable, direct inhibitor of both PDK1 and Akt that blocks phosphorylation of Akt at both Ser<sup>473</sup> and Thr<sup>308</sup>. The dual inhibition nature against both PDK1/Akt and Flt3/PIM signaling pathways allows effective killing of AML cells (Average IC<sub>50</sub> = 1.05, 1.91, and 0.43  $\mu$ M for AML with wild-type Flt3, single mutant ITD/D835, and double mutant Flt3-ITD-TDK, respectively) that are otherwise resistant to inhibitors targeting only the PDK1/Akt pathway. Purity:  $\geq 98\%$  by HPLC (sum of two isomers). M.W. 224.2



Cat. No. 521275

5 mg

€209


Ref.: Zeng, Z., et al. 2006. *Cancer Res.* 66, 3737; Koul, D., et al. 2006. *Mol. Cancer Ther.* 5, 637; Mandal, M., et al. 2006. *Oral Oncol.* 42, 430; Mandal, M., et al. 2005. *Br. J. Cancer* 92, 1899.

## NEW Inhibitors for PI 3-Kinase/Akt Signaling Pathway (continued...)

### PI 3-K $\alpha$ Inhibitor IV

(3-(4-Morpholinothieno[3,2-d]pyrimidin-2-yl)phenol, HCl)

A cell-permeable, potent, and isoform-selective inhibitor of PI 3-kinases ( $IC_{50}$  = 2 nM, 16 nM, 660 nM, and 220 nM for p110 $\alpha$ , p110 $\beta$ , p110 $\gamma$ , and PI 3-K C2 $\beta$ , respectively) and inhibits non-PI 3-K kinases only at much higher concentrations ( $IC_{50}$   $\geq$  3.4  $\mu$ M for Cdk2/E, KDR, PKA, and PKC $\alpha$ ). *Purity*:  $\geq$ 95% by HPLC. M.W. 386.3



Cat. No. 528111 5 mg €167

Ref.: Hayakawa, M., et al. 2006. *Bioorg. Med. Chem.* 14, 6847.

### PI 3-K $\alpha$ Inhibitor VIII

(1E-Bromoimidazopyridinyl-methylene-methyl-methyl-nitrobenzenesulfonylhydrazide, HCl)

A cell-permeable, potent PI 3-K $\alpha$  selective inhibitor ( $IC_{50}$  = 0.3 nM, 40 nM, 100 nM and 850 nM for p110 $\alpha$ , p110 $\gamma$ , PI 3-K C2 $\beta$ , and p110 $\beta$ , respectively). *Purity*:  $\geq$ 95% by HPLC. M.W. 524.8

Cat. No. 528116 5 mg €129

Ref.: Hayakawa, M., et al. 2006. *Bioorg. Med. Chem.* 15, 5837.

### PI 3-K $\gamma$ Inhibitor VII

(5-(Benzo[1,3]dioxol-5-ylmethylene)-thiazolidine-2,4-dione)

A cell-permeable, potent, and ATP-competitive inhibitor of PI 3-K $\gamma$  ( $IC_{50}$  = 70 nM) with moderate selectivity over PI 3-K $\alpha$ ,  $\beta$ , and  $\delta$  isoforms ( $IC_{50}$  = 0.24  $\mu$ M, 1.45  $\mu$ M and 1.70  $\mu$ M, respectively). *Purity*:  $\geq$ 98% by HPLC. M.W. 249.2


Cat. No. 528114 5 mg €91

Ref.: Ferrandi, C., et al. 2007. *J. Pharmacol. Exp. Ther.* 322, 923.

### PI 3-K $\gamma$ /CKII Inhibitor

(5-(4-Fluoro-2-hydroxyphenyl)furan-2-ylmethylene)thiazolidine-2,4-dione

A cell-permeable, potent, and ATP-competitive inhibitor of PI 3-K $\gamma$  and CKII ( $IC_{50}$  = 20 nM). It inhibits other PI 3-K isotypes ( $IC_{50}$  = 0.94, 20, and 20  $\mu$ M for  $\alpha$ ,  $\beta$ ,  $\delta$ , respectively) and MKK7 $\beta$  ( $IC_{50}$  > 10  $\mu$ M) only at much higher concentrations. *Purity*:  $\geq$ 98% by HPLC. M.W. 305.3




Cat. No. 528112 5 mg €130

Ref.: Pomel, V., et al. 2006. *J. Med. Chem.* 49, 3857.

### Anti-PDK1 (1-556) Rabbit pAb

Polyclonal IgG, liquid, undiluted serum. Immunogen used was full-length recombinant human PDK1. Recognizes the ~60 kDa PDK1 protein in HEK293 cells. Also recognizes ~40 kDa and ~17 kDa unidentified proteins. Suitable for immunoblotting.



Detection of human PDK1 by immunoblotting. Samples: full-length, recombinant human PDK1 (lane 2) and whole cell lysates (40  $\mu$ g) from HEK293 cells (lane 3). Primary antibody: Anti-PDK1 (1-556) Rabbit pAb (1:3000). Detection: chemiluminescence.

Cat. No. ST1115 50  $\mu$ l €117

## NEW Recombinant PI 3-Kinases

Name	Cat. No.	Comments	Size	Price
PI 3-K $\beta$ , p100b/p85 $\alpha$ , Human Recombinant, <i>S. frugiperda</i>	526554	Recombinant, human PI 3-kinase $\beta$ -isoform. This active complex is suitable for the study of activity regulation and inhibitor screening. <i>Purity</i> $\geq$ 90% by SDS-PAGE.	5 $\mu$ g	€158
PI 3-K $\gamma$ , His•Tag®, Human, Recombinant, <i>S. frugiperda</i>	526556	Recombinant, human PI 3-Kinase $\gamma$ -isoform with a His•Tag® sequence at the N-terminus. This active complex is suitable for studying the regulation of activity and inhibitor screening. <i>Purity</i> $\geq$ 95% by SDS-PAGE.	5 $\mu$ g	€158
PI 3-K $\delta$ , p110 $\delta$ /p85 $\alpha$ , GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	526558	Recombinant, human PI 3-kinase $\delta$ -isoform. The p110 $\delta$ subunit has a GST sequence for purification of the heterodimer. The active complex is suitable for studying the regulation of activity and inhibitor screening.	5 $\mu$ g	€158
PI 3-K NT-frag., His•Tag® fusion	526555	Recombinant, human protein containing the N-terminal 483 aa of human PI 3-kinase (P3C2A, PI 3-K C2 $\alpha$ ) with one mutation (N483K) expressed in <i>E. coli</i> with N-terminal His•Tag® and S•Tag™ sequences. Useful as a substrate for protein tyrosine kinases in <i>in vitro</i> assays, but has no intrinsic kinase activity. <i>Purity</i> : >90% by SDS-PAGE.	50 $\mu$ g	€116

## Antibodies for PI 3-Kinase Research

Name	Cat. No.	Comments	Size	Price
Anti-PI-3-Kinase Mouse mAb (AB6)	528107	Lyophilized, monoclonal IgG <sub>1</sub> , purified. Immunogen used was a recombinant human p85 $\alpha$ expressed in <i>E. coli</i> . Recognizes the ~85 kDa p85 $\alpha$ regulatory subunit of PI 3-kinase. Does not cross-react with p85 $\beta$ . Reacts with human, mouse, and rat. <b>IB, IC, IP</b>	100 $\mu$ g	€335
Anti-PI 3-Kinase p110 $\delta$ , C-Terminal (1026-1044) Rabbit pAb	526553	Liquid, polyclonal IgG, affinity purified. Immunogen used was a synthetic peptide corresponding to a distinct C-terminal region of human PI 3-kinase p110 $\delta$ , conjugated to KLH. Recognizes a ~110 kDa human PI-3 kinase p110 $\delta$ protein. <b>IB, IC</b>	100 $\mu$ l	€298
PhosphoDetect™ Anti-PTEN (pSer <sup>380</sup> ) Rabbit pAb	ST1072	Liquid, polyclonal IgG, purified. Immunogen used was a synthetic phosphopeptide corresponding to amino acids surrounding the Ser <sup>380</sup> phosphorylation site of human PTEN. Recognizes the ~54 kDa PTEN protein phosphorylated at Ser <sup>380</sup> . Reacts with human, mouse, and rat. <b>IB, IC, IP, PS</b>	50 $\mu$ l	€173
PhosphoDetect™ Anti-PDK1 (pSer <sup>241</sup> ) Rabbit pAb	ST1073	Liquid, IgG. Immunogen used was a synthetic phosphopeptide corresponding to amino acids surrounding the Ser <sup>241</sup> phosphorylation site of human PDK1. Recognizes the ~63 kDa PDK1 protein phosphorylated at Ser <sup>241</sup> . Reacts with human, mouse, and rat. <b>IB, IC, IP</b>	50 $\mu$ l	€173
Anti-SMG1 Rabbit pAb (Anti-PI 3-Kinase-Related Kinase SMG1)	DR1035	Liquid, polyclonal IgG, affinity purified. Immunogen used was a synthetic peptide corresponding to amino acids near the C-terminus of human SMG1. Epitope lies within amino acids 1000-1050. Recognizes the ~340 kDa SMG protein in HeLa cell nuclear extracts. <b>IB</b>	50 $\mu$ g	€130


**IB:** immunoblotting; **IC:** immunocytochemistry; **IP:** immunoprecipitation; **mAb:** monoclonal; **pAb:** polyclonal; **PS:** paraffin sections

## NEW Apoptosis Research Products

### MDM2 Antagonist III

(2-Benzyl-3-(4-chlorophenyl)-3-(3-hydroxypropoxy)-2,3-dihydroisoindol-1-one)

A cell-permeable isoindolinone compound that binds to MDM2 and disrupts MDM2-p53 interaction ( $IC_{50}$  = 15.9  $\mu$ M). Shown to upregulate p53-dependent luciferase activity and cellular levels of MDM2 and p21 in SJSA cells. *Purity:*  $\geq 95\%$  by HPLC. M.W. 407.9



Cat. No. 444149


10 mg

€135

Ref.: Hardcastle, I.R., et al. 2006. *J. Med. Chem.* 49, 6209; Hardcastle, I.R., et al. 2006. *Bioorg. Med. Chem. Lett.* 15, 1515.

### Procaspase-3 Activator, PAC-1

A cell-permeable activator of procaspase-3 ( $EC_{50}$  = 220 nM). Substitution of any of the three aspartate residues in the enzyme's safety-catch region greatly reduces the *in vitro* activation efficiency ( $EC_{50}$  = 2.77  $\mu$ M, 113  $\mu$ M, and 131  $\mu$ M for mutant procaspase-3 with DAD, DDA, and ADD sequence, respectively;  $EC_{50}$  = 4.5  $\mu$ M for wild-type procaspase-7 with DTD sequence). Potency of apoptosis induction by PAC-1 in various cells strongly correlates with cellular levels of procaspase-3 expression. *Purity:*  $\geq 95\%$  by HPLC. M.W. 392.5



Cat. No. 529661

10 mg

€116

Ref.: Putt, K.S., et al. 2006. *Nat. Chem. Biol.* 2, 543.

### G $\beta$ $\gamma$ Modulator I, M119

(NSC119910)

A cell-permeable xanthene compound that binds to G $\beta$  $\gamma$  with high affinity ( $IC_{50}$  = 200 nM in competition ELISA using biotinylated-G $\beta_1\gamma_2$ ) and modulates G $\beta$  $\gamma$  interaction with G $\alpha_{11}$  and GRK2 ( $IC_{50}$  = 400 nM and 5  $\mu$ M, respectively). Shown to block G $\beta$  $\gamma$ -dependent activation of down-stream effectors, PLC $\beta$ 2, PLC $\beta$ 3, and PI 3-K $\gamma$ , both *in vitro* and *in vivo*.

*Purity:*  $\geq 95\%$  by HPLC. M.W. 370.4

Cat. No. 371707

5 mg

€86

Ref.: Bonacci, T.M., et al. 2006. *Science* 312, 443.

## NEW Antibodies for Apoptosis Research

Name	Cat. No.	Comments	Size	Price
Anti-PARC (1-763) Rabbit pAb	DR1040	Liquid, polyclonal IgG, undiluted serum. Immunogen used was a recombinant protein consisting of amino acids 1-763 of human PARC fused to a His•Tag® sequence. Recognizes a ~270 kDa PARC protein in U2OS cells. <b>IB, IP</b>	50 µl	€117
Anti-ASC Rabbit pAb	ST1121	Liquid, polyclonal IgG, undiluted serum. Immunogen used was a full-length recombinant human ASC, expressed in <i>E. coli</i> . Recognizes the ~21 kDa ASC (apoptosis-associated speck-like protein containing a CARD) protein in HT-29 cells. <b>IB, IP</b>	50 µl	€117
Anti-APAF-1 Rabbit pAb	AP1052	Liquid, polyclonal IgG, protein A purified. Immunogen used was a full-length recombinant human APAF-1 fused to a His•Tag® sequence and expressed in <i>E. coli</i> . Recognizes the ~130 kDa APAF-1 protein in HeLa cells. <b>IB</b>	50 µl	€117

**IB:** immunoblotting; **IP:** immunoprecipitation; **pAb:** polyclonal

### DAPK1, GST-Fusion, Human, Recombinant, *S. frugiperda*

Recombinant, human death associated protein kinase (DAPK1) fused at the N-terminus to a GST-His<sub>6</sub>-thrombin cleavage site sequence and expressed in *S. frugiperda* insect cells using a baculovirus expression system. DAPK1 is a Ca<sup>2+</sup>/calmodulin-dependent serine/threonine kinase that acts as a positive regulator of apoptosis. *Specific activity:* ≥50 pmol/min/µg protein. *Kinase activity is measured as the molar amount of phosphate incorporated into IAKRRRLSSLRASTSKSESSQK peptide substrate per minute per mg protein at 30°C, using variable concentrations from 0.1 µM to 0.391 µM ATP.*


**Cat. No. 324782**      **10 µg**      **€265**

Ref.: Bialik, S. and Kimchi, A., 2006. *Annu. Rev. Biochem.* **75**, 189; Shohat, G., et al. 2001. *J. Biol. Chem.* **276**, 47460; Deiss, L.P., et al. 1995. *Genes Dev.* **9**, 15.

## Apoptosis Research Kits

### Active Caspase-9 Assay Kit

A 96-well based fluorimetric caspase-9 assay kit that captures active caspase-9 complexed with APAF-1. Active caspase-9 cleaves precursor caspase-3 and activates it, which in turn releases AFC from DEVD-AFC. The fluorescence is measured in a plate reader. Each kit is suitable for up to 480 tests. Suitable for use with human cell lines.




Activated extract and precursor caspase-3 are required for DEVD-AFC cleavage. Caspase-9 in activated and control Jurkat cell extracts (5 x 10<sup>5</sup> cells) were captured in wells coated with caspase-9 capture antibody. Wells were washed and precursor caspase-3 was added and after 60 min. incubation, cleavage of DEVD-AFC by caspase-3 was measured using a fluorescent plate reader. Precursor caspase-3 only (C3 only), activated extracts only (act only), a control extract with precursor caspase-3 (con +C3), and activated extract with precursor caspase-2 (act+C3) were used in this assay. A unit of caspase-9 activity is defined as the amount of active caspase-9 required to activate sufficient caspase-3 to cleave DEVD-AFC at a rate of 1 RFU/minute.

**Cat. No. CBA047**      **1 kit**      **€394**

### Y-27632

A highly potent, cell-permeable, selective, ATP-competitive inhibitor of Rho-associated protein kinases ( $K_i = 140$  nM for p160<sup>ROCK</sup>). Also inhibits ROCK-II with equal potency. Blocks dissociation-induced apoptosis in human embryonic stem cells and increase cloning efficiency. *Purity:* ≥95% by HPLC. M.W. 338.3.



Sold under license of U.S. Patent 4,997,834 and PCT Application W098/06,433A1 and under license from Mitsubishi Tanabe Pharma Corporation.

**Cat. No. 688000**      **1 mg**      **€153**  
                                  **5 mg**      **€596**



## Apoptosis Research Kits *(continued...)*

### p21<sup>WAF1</sup> ELISA Kit

Format: 96-well plate


Sensitivity: 0.1 U/ml

Assay range: 0.1–20 U/ml

Assay time: 4 h

Sample type: Cell extracts or tissue culture media

A sandwich ELISA method for assay of WAF1. Suitable for use with human cell line extracts or tissue culture media.



Time, drug, and cell line-dependent changes in WAF1 levels detected by the WAF1 assay. MCF-7, HeLa, and HS27 cells were treated with dexamethasone (1  $\mu$ M), doxorubicin (0.2  $\mu$ g/ml), and hydroxyurea (2.5 mM) and tested for WAF1 levels at different time points.

Cat. No. QIA18

1 kit

€633

### Live/Dead Double Staining Kit

Assay time: 0.5 h

Sample type: Cell suspensions or adherent cells

This kit is based on fluorescence microscopic detection method and uses a cell-permeable green fluorescent Cyto-dye (Exc. max.: 488 nm; Em. max.: 518 nm) to stain live cells, and propidium iodide (Exc. max.: 488 nm; Em. max.: 615 nm) to stain dead cells. Stained live and dead cells can be visualized by fluorescence microscopy using a band-pass filter, which detects FITC and rhodamine. Viable cells stain only with the Cyto-dye, fluorescing green, whereas the dead cells stain with both Cyto-dye (green) and propidium iodide (red), resulting in a yellow fluorescence. This kit can be used with a wide range of species. *Optimal staining conditions may vary among different cell types and should be determined empirically by the investigator.*

Cat. No. QIA76

100 Tests

€283

Ref.: Luther, E., and Kamenstsky, L.A. 1996. *Cytometry* 23, 272; Frey, T., et al. 1995. *Cytometry* 21, 265.



"As a quality control supervisor, Doug was always hard to please."


# The IKK-NF- $\kappa$ B System: A Target for Inflammation and Cancer

NF- $\kappa$ B is an important regulator of inflammatory and autoimmune responses, cell proliferation, and apoptosis. The activation of NF- $\kappa$ B that occurs via the classical pathway is triggered by bacterial and viral infections and by pro-inflammatory cytokines. Five members of the NF- $\kappa$ B family have been identified: NF- $\kappa$ B1 (p50/p105), NF- $\kappa$ B2 (p52/p100), RelA (p65), RelB, and c-Rel. The p50/RelA (p65) heterodimer is the major Rel/NF- $\kappa$ B complex in most cells. In resting cells, NF- $\kappa$ B is sequestered in the cytoplasm in an inactive form associated with inhibitory molecules, such as I $\kappa$ B. Activation of NF- $\kappa$ B is achieved through the action of I $\kappa$ B kinases (IKK), which phosphorylate I $\kappa$ B and allow its polyubiquitination and degradation by the 26S proteasome complex. This allows the translocation of NF- $\kappa$ B from the cytoplasm to the nucleus where it binds to NF- $\kappa$ B response elements in target genes and regulates their transcription.

In the nucleus, recruitment of NF- $\kappa$ B to its target genes and regulation of NF- $\kappa$ B-mediated transcriptional activation are mediated mainly by phosphorylation and acetylation of NF- $\kappa$ B that enhance its DNA binding activity. Several protein

kinases, including PKA, PKC $_{\alpha}$ , and casein kinase II directly phosphorylate p65 (at Ser<sup>276</sup>, Ser<sup>311</sup>, Ser<sup>529</sup>, respectively). However, others like PI 3-K/Akt and NF- $\kappa$ B-inducing kinase phosphorylate IKK, which in turn phosphorylates p65 at Ser<sup>536</sup>. Reversible acetylation of NF- $\kappa$ B can also determine its active or inactive state. p300 and CBP acetyltransferases play a major role in the acetylation of p65, principally targeting Lys<sup>218</sup>, 221, 310. Deacetylation of p65 by histone deacetylase 3 promotes its binding to I $\kappa$ B that leads to rapid export of deacetylated NF- $\kappa$ B from the nucleus into the cytoplasm. One of the target genes activated by NF- $\kappa$ B is that encoding I $\kappa$ B $\alpha$ . Newly synthesized I $\kappa$ B $\alpha$  can enter the nucleus, remove NF- $\kappa$ B from DNA, and export the NF- $\kappa$ B/I $\kappa$ B complex back to the cytoplasm to restore its original latent state.

In most cancer cells NF- $\kappa$ B is constitutively active and resides in the nucleus, which not only protects cancer cells from apoptotic cell death, but may also enhance their growth activity. Hence, designing anti-tumor agents to block NF- $\kappa$ B activity has great therapeutic value. ■




## NEW Inhibitors of NF- $\kappa$ B Activation Scheme

### NF- $\kappa$ B Activation Inhibitor IV

((E)-2-Fluoro-4'-methoxystilbene)

A cell-permeable trans-stilbene Resveratrol analog that is about 130-fold more potent than Resveratrol in inhibiting TNF- $\alpha$ -stimulated NF- $\kappa$ B reporter activity in 293T cells ( $IC_{50}$  = 150 nM). *Purity*:  $\geq 98\%$  by HPLC. M.W. 228.1




Cat. No. 481412 10 mg €113

Ref.: Heynekamp, J.J., et al. 2006. *J. Med. Chem.* 49, 7182.

### IKK-2 Inhibitor VIII

(2-Amino-6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-4-(4-piperidinyl)-3-pyridinecarbonitrile)

A cell-permeable, selective inhibitor of IKK-2 ( $IC_{50}$  = 8.5 and 250 nM for IKK-2 and IKK-1, respectively). Exhibits little effect towards IKK-3, Syk, and MKK4 ( $IC_{50}$  > 20  $\mu$ M). *Purity*:  $\geq 95\%$  by HPLC. M.W. 364.4




Cat. No. 401487 1 mg €121

Ref.: Murata, T., et al. 2004. *Bioorg. Med. Chem. Lett.* 14, 4019.

### Aurothiomalate

A gold(I) compound that inhibits the activity of IKK ( $ID_{50}$  = 10.9  $\mu$ M) and disrupts PB1 (Phox and Bem1p) domain-mediated interactions between Par6 and PKC $\zeta$  ( $IC_{50}$  ~ 1  $\mu$ M) by modifying cysteine residues within the catalytic domain of IKK and the PB1 domain of PKC $\zeta$ . Also inhibits PKC $\zeta$ -dependent Rac1 activation in A549 cells. *Purity*:  $\geq 98\%$  (Gold content). M.W.368.1



Cat. No. 189401 50 mg €79

Ref.: Erdogan, E., et al. 2006. *J. Biol. Chem.* 281, 28450; Stallings-Mann, M., et al. 2006. *Cancer Res.* 66, 1767; Jeon, K.I., et al. 2000. *J. Immunol.* 164, 5981; Handel, M.L., et al. 1995. *Proc. Natl. Acad. Sci. USA* 92, 4497.

## Now Available...Ready to Use

### InSolution™ NF- $\kappa$ B Activation Inhibitor

A 10 mM (1 mg/281  $\mu$ l) solution of NF- $\kappa$ B Activation Inhibitor (Cat. No. 481406) in DMSO.

Cat. No. 481407 1 mg €71

## Antibodies for NF- $\kappa$ B Activation Research

Name	Cat. No.	Comments	Size	Price
Anti-NF- $\kappa$ B (p50) (Ab-1) Rabbit pAb	PC136	Liquid, polyclonal IgG, diluted serum. Immunogen used was a synthetic peptide corresponding to amino acids near the N-terminal domain of human NF- $\kappa$ B p50. Recognizes the NF- $\kappa$ B p50 protein in Daudi cells. <b>ELISA, GS, IB, IP</b>	20 $\mu$ l 100 $\mu$ l	€66 €287
Anti-NF- $\kappa$ B (p65, RelA) (Ab-1) Rabbit pAb	PC137	Liquid, Polyclonal IgG, undiluted serum. Immunogen used was a synthetic peptide corresponding to amino acids near the C-terminal domain of human NF- $\kappa$ B p65 (RelA), conjugated to KLH. Recognizes NF- $\kappa$ B p65 (RelA) protein in Daudi cells. <b>GS, IB, IP</b>	20 $\mu$ l 100 $\mu$ l	€66 €329
Anti-NF- $\kappa$ B (p65, RelA) (Ab-2) Rabbit pAb	PC138	Liquid, polyclonal IgG. Immunogen used was a synthetic peptide corresponding to amino acids near the N-terminal domain of human NF- $\kappa$ B p65 (RelA), conjugated to KLH. Recognizes NF- $\kappa$ B p65 (RelA) protein in Daudi cells. <b>ELISA, GS, IB, IP</b>	100 $\mu$ l	€339
Anti-NF- $\kappa$ B (p65) Mouse mAb (2A12A7)	ST1047	Liquid, monoclonal IgG $_{2a}$ , purified. Immunogen used was a recombinant protein containing ~175 amino acids from the C-terminus of human NF- $\kappa$ B p65 (RelA). Recognizes NF- $\kappa$ B p65 (RelA) protein in K562, HeLa, and A431 cells. <b>ELISA, GS, IB</b>	100 $\mu$ l	€277


**ELISA**: enzyme-linked immunosorbent assay; **GS**: gel-shift; **IB**: immunoblotting; **IP**: immunoprecipitation; **mAb**: monoclonal; **pAb**: polyclonal

## Antibodies for NF- $\kappa$ B Activation Research (continued...)

### Anti-MAVS Rabbit pAb

Liquid, polyclonal IgG, purified. Immunogen used was a synthetic peptide corresponding to amino acids in middle region of human MAVS. Recognizes the ~56 kDa MAVS protein in Saos-2 cells. MAVS is essential for NF- $\kappa$ B and IRF3 activation by RNA viruses. Suitable for immunoblotting and immunoprecipitation.

Cat. No. ST1116                      50  $\mu$ g                      €117




Lane 1: Detection of human MAVS by immunoblotting. Sample: 20  $\mu$ g of Saos-2 cell lysates. Primary antibody: Anti-MAVS Rabbit pAb (Cat. No. ST1116) (0.1  $\mu$ g/ml). Detection: chemiluminescence.

Lane 2: Detection of MAVS by immunoprecipitation followed by immunoblotting. Antibody was used at 5  $\mu$ g/500  $\mu$ g total protein.

## NEW Protein Kinase Inhibitors

### Cdk1 Inhibitor IV, RO-3306

A cell-permeable, potent, and ATP-competitive inhibitor of Cdk1 ( $K_i$  = 35 nM and 110 nM for Cdk1/B1 and Cdk1/A, respectively). It affects Cdk2/E, PKC $\delta$ , and SGK only at much higher concentrations ( $K_i$  = 340, 318, and 497 nM, respectively). *Purity*:  $\geq 95\%$  by HPLC. M.W. 351.5




Cat. No. 217699                      5 mg                      €142

Ref.: Vassilev, L.T., et al. 2006. *Proc. Natl. Acad. Sci. USA* 103, 10660.

### Casein Kinase II Inhibitor III, TBCA

((E)-3-(2,3,4,5-Tetrabromophenyl)acrylic acid)

A cell-permeable, potent, and ATP-competitive inhibitor of Casein Kinase II ( $IC_{50}$  = 110 nM,  $K_i$  = 77 nM) with greater selectivity than TBB (Cat. Nos. 218697 and 218708) and DMAT (Cat. Nos. 218699 and 218706) against a panel of 28 commonly studied kinases. Shown to induce apoptosis in Jurkat cells ( $DC_{50}$  = 7.7  $\mu$ M). *Purity*:  $\geq 95\%$  by HPLC. M.W. 463.8



Cat. No. 218710                      5 mg                      €90

Ref.: Pagano, M.A., et al. 2006. *Chembiochem* 8, 129.

### Cdk/Cyclin Inhibitory Peptide III

(Ac-RWIMYF-NH $_2$ )

A protease resistant, all D-amino acid hexapeptide that selectively binds to a conserved region of cyclin A with high-affinity ( $K_d$  ~ 102 nM) and disrupts the formation of Cdk/cyclin complex. Shown to inhibit the kinase activity of Cdk2/cyclin A, Cdk1/cyclin B1 and Cdk6/cyclin D3 ( $IC_{50}$  = 1.1  $\mu$ M, 2.0  $\mu$ M and 6.4  $\mu$ M, respectively) in a non-competitive manner with respect to both ATP and protein substrates. Its cell-permeable analog, TAT-NBI1 is also available (Cat. No. 238808). *Purity*:  $\geq 97\%$  by HPLC. M.W. 956.2


Cat. No. 238807                      5 mg                      €171

Ref.: Canela, N., et al. 2006. *J. Biol. Chem.* 281, 35942.

### JNK Inhibitor IX

(N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-1-naphthamide)

A potent and ATP binding site-targeting inhibitor of JNK2 and JNK3 ( $pIC_{50}$  = 6.5 and 6.7, respectively) with little or no activity against JNK1, p38 $\alpha$ , and a panel of more than 30 other kinases ( $pIC_{50}$  <5.0). *Purity*:  $\geq 95\%$  by HPLC. M.W. 350.4



Cat. No. 420136                      5 mg                      €105

Ref.: Angell, R.M., et al. 2007. *Bioorg. Med. Chem. Lett.* 17, 1296.




## **NEW** Protein Kinase Inhibitors (continued...)

### PDGF Receptor Tyrosine Kinase Inhibitor V

(N-(4-((6,7-Dimethoxy-4-quinoyl)oxy)phenyl)-N'-(2-methylbenzoyl)thiourea)

A cell-permeable, potent, ATP-competitive, and reversible inhibitor of PDGFR tyrosine kinase activity ( $IC_{50}$  = 4 and 7.6 nM in ligand-induced cellular PDGFR phosphorylation and in *in vitro* kinase activity, respectively). Inhibits c-kit receptor only at much higher concentrations ( $IC_{50}$  = 434 and 234 nM in receptor phosphorylation and kinase activity, respectively). *Purity*:  $\geq 95\%$  by HPLC. M.W. 527.6



Cat. No. 521234

1 mg


€153

Ref.: Furuta, T., et al. 2006. *J. Med. Chem.* 49, 2186.

### Quercetagenin

(3,3',4',5,6,7-Hexahydroxyflavone)

A cell-permeable flavanol compound that acts a potent, ATP-competitive, and reversible inhibitor of PIM1 kinase ( $IC_{50}$  = 340 nM). Exhibits  $\geq 7$ -fold selectivity over 8 other kinases tested, including PIM2 ( $IC_{50}$  = 3.45  $\mu$ M). Shown to induce growth arrest ( $ED_{50}$  = 3.8  $\mu$ M) in PIM1-expressing RWPE2 cells. *Purity*:  $\geq 95\%$  by HPLC. M.W. 318.3



Cat. No. 551590

5 mg


€207

Ref.: Holder, S., et al. 2007. *Mol. Cancer Ther.* 6, 163.

### Syk Inhibitor IV, BAY 61-3606

(2-(7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino)-nicotinamide, HCl)

A cell-permeable, potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase ( $IC_{50}$  = 10 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src even at concentrations as high as 4.7  $\mu$ M. *Purity*:  $\geq 97\%$  by HPLC. M.W. 462.9



Cat. No. 574714

2 mg


€122

Ref.: Yamamoto, N., et al. 2003. *J. Pharm. Exp. Ther.* 306, 1174.

### Wee1/Chk1 Inhibitor

(6-Butyl-4-(2-chlorophenyl)-9-hydroxypyrrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione)

A potent, ATP-competitive inhibitor of Wee1 and Chk1 ( $IC_{50}$  = 97 and 47 nM, respectively). *Purity*:  $\geq 95\%$  by HPLC. M.W. 346.3



Cat. No. 681637

1 mg


€108

Ref.: Palmer, B.D., et al. 2006. *J. Med. Chem.* 49, 4896; Squire, C.J., et al. 2005. *Structure* 13, 541.

### Wee1 Inhibitor II

(6-Butyl-4-(2-chlorophenyl)-9-hydroxypyrrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione)

A potent, ATP-binding site-targeting inhibitor of Wee1 ( $IC_{50}$  = 59 nM) with a  $\sim 590$ -fold selectivity over the related checkpoint kinase Chk1 ( $IC_{50}$  = 35  $\mu$ M). *Purity*:  $\geq 97\%$  by HPLC. M.W. 418.9



Cat. No. 681641

1 mg

€105

Ref.: Palmer, B.D., et al. 2006. *J. Med. Chem.* 49, 4896.

## NEW Protein Kinase Activity Kit

### K-LISA™ Aurora Kinase Activity Kit


Format: 96-well plate

Sensitivity: 16 ng for Aurora A; 11 ng for Aurora B

Assay range: 20–1000 ng

Sample type: Purified enzyme or enzyme immunoprecipitated from cell lysates

An ELISA-based activity assay kit for measuring the kinase activity of purified or partially purified Aurora A and Aurora B, *in vitro* Aurora A and Aurora B inhibitor screening, and for assessing the regulation of Aurora A and Aurora B in cell signaling. This kit utilizes a biotinylated peptide substrate (ARTKQTARKSTGGKAPRKQLA-GGK-biotin) that is phosphorylated on serine by Aurora A and Aurora B. The phosphorylated substrate is detected with the Phospho-Histone H3 Antibody, followed by HRP-Antibody Conjugate and color development with TMB Substrate.



Cat. No. CBA051

1 kit

€339

### NEW Aurora A, His•Tag®, Human Rec., *S. frugiperda*

A full-length, recombinant, human Aurora A kinase (amino acids 2–403; Accession: NM\_003600) fused at the N-terminus to a His•Tag® sequence and expressed in Sf9 insect cells using a baculovirus expression system.

Specific activity:  $\geq 120$  U/ $\mu$ g protein. One unit is defined as the amount of enzyme that will phosphorylate 1 pmol of Ser/Thr 1 peptide substrate per min at 30°C, pH 7.4. Purity:  $\geq 90\%$  by SDS-PAGE. M.W. 50,000.

Cat. No. 481413

10  $\mu$ g

€239

### PhosphoDetect™ Hsp27 (pSer<sup>78/82</sup>) ELISA Kit

Format: 96-well plate


Assay range: 0.1–10 ng/ml; Assay time: 4.5 h

A quantitative sandwich ELISA for assay of Hsp27 phosphorylated at Ser<sup>78</sup> and Ser<sup>82</sup>. Suitable for use with cell lysates, tissue extracts, and biological fluids. The assay utilizes an Hsp27-specific monoclonal antibody, immobilized on the wells of a 96-well plate to capture Hsp27.

Cat. No. CBA078

1 kit

€362




## NEW Recombinant Protein Kinases

Name	Cat. No.	Comments	Size	Price
CDK1/CycB, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325897	Recombinant, human Cdk1 (amino acids 1-297) and recombinant human cyclin B (amino acids 1-433), each fused to a GST-His <sub>6</sub> -thrombin cleavage site sequence at their respective N-termini and co-expressed in <i>S. frugiperda</i> using a baculovirus expression system. M.W. Cdk1 = 63,882 Da; M.W. cyclin B = 78, 925 Da. <i>Specific activity</i> : $\geq 2$ pmol/min/ $\mu$ g protein.	10 $\mu$ g	€257
CDK2/CycA, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325898	Recombinant, human CDK2 (amino acids 1-298) and recombinant, human cyclin A (amino acids 1-432), each fused to a GST-thrombin cleavage site sequence at their respective N-termini and co-expressed in <i>S. frugiperda</i> using a baculovirus expression system. M.W. CDK2 = 60,200 Da; M.W. cyclin A = 74,900 Da. <i>Specific activity</i> : $\geq 9$ pmol/min/ $\mu$ g protein.	10 $\mu$ g	€257
CDK4/CycD1, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325899	Recombinant, human CDK4 and recombinant, human cyclin D1, each fused to a GST-thrombin cleavage site sequence at their respective N-termini and co-expressed in <i>S. frugiperda</i> using a baculovirus expression system. M.W. CDK4 = 59,700 Da; M.W. cyclin D1 = 60,000 Da. <i>Specific activity</i> : $\geq 91$ pmol/min/ $\mu$ g protein.	10 $\mu$ g	€257
CDK6/CycD1, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325900	Recombinant, human CDK6 and recombinant, human cyclin D1, each fused to a GST-thrombin cleavage site sequence at their respective N-termini and co-expressed in <i>S. frugiperda</i> using a baculovirus expression system. M.W. CDK6 = 63,300 Da; M.W. cyclin D1 = 60,000 Da. <i>Specific activity</i> : $\geq 11$ pmol/min/ $\mu$ g protein.	10 $\mu$ g	€257
NEK2, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325888	Recombinant, human Never in mitosis gene A-related protein kinase 2 (NEK2) fused at the N-terminus to a GST-His <sub>6</sub> -thrombin cleavage site sequence and expressed in <i>S. frugiperda</i> using a baculovirus expression system. NEK2 is a member of a serine/threonine-protein kinase family that plays an important role in mitotic regulation. <i>Specific activity</i> : $\geq 15$ pmol/min/ $\mu$ g protein.	10 $\mu$ g	€265
PAK1, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325889	Recombinant, human p21-activated protein kinase 1 fused at the N-terminus to a GST-His <sub>6</sub> -thrombin cleavage site sequence and expressed in <i>S. frugiperda</i> using a baculovirus expression system. <i>Specific activity</i> : $\geq 325$ pmol/min/ $\mu$ g protein.	10 $\mu$ g	€265
WEE1, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325896	Recombinant, human WEE1 fused at the N-terminus to a GST-His <sub>6</sub> -thrombin cleavage site sequence and expressed in <i>S. frugiperda</i> using a baculovirus expression system. <i>Specific activity</i> : $\geq 1$ pmol/min/ $\mu$ g protein.	10 $\mu$ g	€257

## NEW Inhibitors for Angiogenesis Research

### FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074

A cell-permeable, potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptor tyrosine kinases ( $IC_{50}$  = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src kinases only at much higher concentration ( $IC_{50}$  = 17.6  $\mu$ M, 19.8  $\mu$ M, respectively). Blocks the autophosphorylation of endogenous FGFR1 ( $IC_{50}$  <5 nM) and overexpressed VEGFR2 ( $IC_{50}$  <200 nM) in NIH-3T3 cells *in vitro*, and FGF- and VEGF-induced angiogenesis in mice *in vivo*. *Purity*:  $\geq 97\%$  by HPLC. M.W. 523.7




**Cat. No. 341607**      **2 mg**      **€116**

Ref.: Koziczak, M., et al. 2004. *Oncogene* 23, 3501; Trudel, S., et al. 2004. *Blood* 103, 3521; Skaper, S.D., et al. 2000. *J. Neurochem.* 75, 1520; Mohammadi, M., et al. 1998. *EMBO J.* 17, 5896.

### Flt3 Inhibitor III

(5-Phenyl-N-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-thiazolamine)

A cell-permeable, potent, ATP binding site-targeting inhibitor of Flt3 ( $IC_{50}$  = 50 nM). It inhibits c-Kit, KDR, c-Abl, Cdk1, c-Src, and Tie-2 only at much higher concentrations ( $IC_{50}$  = 0.26, 0.91, 1.2, 2.1, 2.8, and 8.0  $\mu$ M, respectively). Blocks Flt3-dependent cell proliferation in a dose-dependent manner. *Purity*:  $\geq 95\%$  by HPLC. M.W. 365.5



**Cat. No. 343022**      **5 mg**      **€116**


Ref.: Furet, P., et al. 2006. *J. Med. Chem.* 49, 4451.

## NEW Inhibitors for Angiogenesis Research (continued...)

### VEGF Receptor 2/3 Tyrosine Kinase Inhibitor

(3-(Indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione)

A cell-permeable, potent and ATP-competitive inhibitor of VEGFR-2 and -3 tyrosine kinase ( $IC_{50}$  = 2.5 nM and 5 nM, respectively) with >100-fold selectivity over 25 other commonly studied kinases. Exhibits excellent *in vivo* anti-angiogenic efficacy in chick embryo assay. *Purity*:  $\geq 97\%$  by HPLC. M.W. 378.4



Cat. No. 676499

5 mg


€144

Ref.: FPeifer, C., et al. 2006. *J. Med. Chem.* **49**, 7549; Peifer, C., et al. 2006. *J. Med. Chem.* **49**, 1271

### VEGF Receptor Tyrosine Kinase Inhibitor IV

(N-(2-Chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea)

A cell-permeable, potent pan-VEGFR tyrosine kinase inhibitor ( $IC_{50}$  = 30 nM, 6.5 nM and 15 nM for VEGFR-1, 2, and 3, respectively). Also inhibits the activity of EphB2, PDGFR- $\alpha$ , PDGFR- $\beta$ , c-Kit and Tie-2 ( $IC_{50}$  = 24 nM, 40 nM, 49 nM, 78 nM and 78 nM, respectively). *Purity*:  $\geq 95\%$  by HPLC. M.W. 472.9.



Cat. No. 676483

500  $\mu$ g

€113

Ref.: Nakamura, K., et al. 2006. *Cancer Res.* **66**, 9134.

## Proteins for Angiogenesis Research

Name	Cat. No.	Comments	Size	Price
Endostatin Protein, Human, Recombinant, <i>Pichia pastoris</i> *	324768	Recombinant, human endostatin expressed in and purified from <i>Pichia pastoris</i> . A ~20 kDa C-terminal fragment of collagen XVIII that acts as a potent inhibitor of angiogenesis and tumor growth in vitro and in vivo. <i>Biological activity</i> : 10 $\mu$ g/ml endostatin will inhibit 50% tube formation in the presence of 10 ng/ml VEGF and 70% tube formation in the presence of 5 ng/ml bFGF.	250 $\mu$ g 1 mg	€209 €546
Endostatin Protein, Mouse, Recombinant, <i>Pichia pastoris</i> *	324769	Recombinant, mouse endostatin. A ~20 kDa C-terminal fragment of collagen XVIII that acts as a potent inhibitor of angiogenesis and tumor growth in vitro and in vivo. <i>Biological activity</i> : 3 $\mu$ g/ml endostatin will inhibit 50% tube formation.	250 $\mu$ g 1 mg	€198 €526
Flt-3, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325880	Recombinant, human Flt-3 fused at the N-terminus to a GST-His <sub>6</sub> -thrombin cleavage site sequence and expressed in <i>S. frugiperda</i> insect cells using a baculovirus expression system. <i>Specific activity</i> : $\geq 25$ pmol/min/ $\mu$ g protein.	10 $\mu$ g	€265
TIE2, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325894	Recombinant, human tunica interna endothelial cell kinase 2 (TIE2) fused at the N-terminus to a GST-His <sub>6</sub> -thrombin cleavage site sequence and expressed in <i>S. frugiperda</i> insect cells using a baculovirus expression system. <i>Specific activity</i> : $\geq 95$ units/ $\mu$ g protein.	10 $\mu$ g	€257
VEGF-R1, GST-Fusion, Human, Recombinant, <i>S. frugiperda</i>	325895	Recombinant, human VEGF-R1 fused at the N-terminus to a GST-His <sub>6</sub> -thrombin cleavage site sequence and expressed in <i>S. frugiperda</i> insect cells using a baculovirus expression system. <i>Specific activity</i> : $\geq 45$ pmol/min/ $\mu$ g protein.	10 $\mu$ g	€257

\* Sold under license of U.S. Patents 6,764,995; 6,746,865; and corresponding patents.


### PhosphoDetect™ Anti-VEGF Receptor 2/3 (pAb-1) Rabbit pAb

Liquid, polyclonal IgG, undiluted serum. Immunogen used was a synthetic phosphopeptide [GLARDIpYKDPDpYVRKGD(C)] corresponding to amino acids in human VEGF Receptor 2/3. Recognizes phosphorylated VEGF receptor 2/3 in human cells. Suitable for immunoblotting and paraffin sections.

Cat. No. PC460

25  $\mu$ l

€245





## Proteins for Angiogenesis Research *(continued...)*

### VEGF ELISA Kit, Human

Sensitivity: 5.0 pg/ml

Assay range: 32.2-1000 pg/ml

Assay time: 4.5 h

A 96-well plate sandwich ELISA assay for human VEGF.

Suitable for use with cell culture media, plasma, and serum.

Detects both natural and recombinant human VEGF.

Cat. No. QIA51

1 kit

€664

Sample Type	Average% Recovery	Range
Cell Culture Media (n=5)	102	95-111%
Serum (n=5)	102	92-115%
EDTA Plasma (n=5)	97	82-113%
Heparin Plasma (n=5)	93	82-102%
Citrate Plasma (n=5)	100	88-113%

The average recovery of VEGF protein, spiked to three levels in five samples is shown

## **NEW** Research Tools for Diabetes Research

### Innozyme Insulysin/IDE Immunocapture Activity Assay Kit

Format: 96-well plate

Detection method: Fluorescence

Assay range: 50-1000 ng/ml


Sample type: cell lysates, tissue extracts, and biological fluids

A specific and sensitive assay kit for measuring active insulysin (IDE) from human, mouse, or rat samples. This kit employs an affinity-purified polyclonal antibody immobilized on a 96-well plate to capture IDE. Activity of captured IDE is measured using a FRET substrate, Mca-GGFLRKHGQ-EDDnp. Substrate is cleaved between R and K, which relieves the internal quenching. (*Exc. max.* 320 nm; *Em. max.* 405 nm).

Cat. No. CBA079

1 kit

€393



Recombinant rat and human IDE was measured using the InnoZyme™ Insulysin/IDE Immunocapture Activity Assay Kit (Cat. No. CBA079). Incubation period: 4 hours at 37°C.


Product	Cat. No.	Comments	Size	Price
Insulin Degrading Enzyme, His•Tag®, Rat, Recombinant, <i>S. frugiperda</i>	407241	A metalloprotease that degrades insulin and a variety of other peptides including amyloid peptides. <i>Specific activity:</i> ≥4 U/mg protein. <i>Purity:</i> ≥90% by SDS-PAGE.	50 µg	€225
Anti-IDE/Insulysin Rabbit pAb	ST1120	Polyclonal IgG, purified. Immunogen: a synthetic peptide corresponding to amino acids at the N-terminus of human IDE/insulysin. Recognizes the ~110 kDa IDE protein in HT1080 cells. Reacts with human. <b>IB, IP</b>	50 µg	€117
Anti-IDE, N-Terminal (97-273) Rabbit pAb	PC730	Polyclonal IgG, undiluted serum. Immunogen: a recombinant protein containing amino acids 97-273 of rat IDE fused to GST. Recognizes the ~115 kDa endogenous and recombinant IDE. Reacts with hamster, human, mouse, rat. <b>ELISA, IB, IC</b>	100 µl	€329

**ELISA:** enzyme-linked immunosorbent assay; **IB:** immunoblotting; **IC:** immunocytochemistry; **IP:** immunoprecipitation; **pAb:** polyclonal

### SecinH3

(N-(4-(5-(1,3-Benzodioxol-5-yl)-3-methoxy-1H-1,2,4-triazol-1-yl)phenyl)-2-(phenylthio)acetamide)

A cell-permeable inhibitor of Sec7-specific GEFs (guanine nucleotide exchange factors) activity that also blocks insulin signaling pathway. Shown to selectively inhibit pIRS-1 by IR and display insulin resistance in mouse model. *Purity: ≥98% by HPLC. M.W. 460.5*



**Cat. No. 565725** **5 mg** **€167**

Ref.: Hafner, M., et al. 2006. *Nature* 444, 941. Fuss, B., et al. 2006. *Nature* 444, 945.

### AMPK, His•Tag®, Human, Recombinant, *S. frugiperda*

Full length recombinant AMPK subunits (A1, B1, and G1) with C-terminal His•Tag® fusions coexpressed in Sf9 insect cells. AMPK is involved in sensing energy levels in the cell due to changes in AMP levels. *Specific activity: ≥2755 nmol/min/mg. Purity: ≥95% by SDS-PAGE.*

**Cat. No. 171536** **5 µg** **€143**

Ref.: Scott, J.W., 2007. *EMBO J.* 26, 806; Minokoshi, Y et al. 2004. *Nature* 428, 569.

### p70S6K, Human, Recombinant, *S. frugiperda*

A full-length, active, recombinant, human p70S6 kinase. *Activity: Kinase activity is measured as the amount of radioactivity incorporated into S6K substrate peptide (CKRRRLASLR) at 30°C, using a final concentration of 50 µM [<sup>32</sup>P] ATP. Purity: ≥75% by SDS-PAGE. M.W. 76,000*

**Cat. No. 506182** **5 µg** **€398**

Ref.: Scott, J.W., 2007. *EMBO J.* 26, 806; Minokoshi, Y et al. 2004. *Nature* 428, 569.

### FKBP12, GST-Fusion, Human, Recombinant, *E. coli*

A full-length recombinant, human FK506 binding protein 12-rapamycin associated protein 1 (FKBP12) fused to GST at the N-terminus and expressed in *E. coli*. FKBP12 is a cytosolic receptor for both rapamycin and FK506 that also serves as a natural cofactor for rapamycin inhibition of mTOR. *Purity: ≥90% by SDS-PAGE. M.W. 12,000*

**Cat. No. 325902** **60 µg** **€185**

Ref.: Jin, Y.J., et al. 1991. *Proc. Natl. Acad. Sci. USA* 88, 6677.

# Calbiochem®

## Diabetes and Obesity

Research Products Brochure

Includes over 450 research products for studying various signaling pathways involved in Diabetes and Obesity Research

- Antibodies
- Assay kits
- Inhibitors
- Enzymes
- Peptides and Substrates



# Stem Cell Marker Antibodies

Stem cells have the unique ability to self-renew and generate additional stem cells as well as to differentiate into various progenitor cells in response to appropriate signals. They are classified as either embryonic stem cells (ES) or adult stem cells (tissue-specific stem cells). ES are derived from the inner cell mass of preimplantation embryos and are considered to be the most pluripotent stem cell population. They can undergo infinite, undifferentiated proliferation *in vitro* and can also differentiate into a wide variety of somatic and extra-embryonic tissues. Adult stem cells, unspecialized cells found in differentiated tissues, can self-renew and differentiate into mature cell types of the specific tissue.

Some advances have been made in the isolation and characterization of adult stem cells. However, tagging and identifying these cells is a challenging task. Fortunately, each cell type has a certain combination of receptors on their surface that makes them distinguishable from other cells. Researchers use this biological uniqueness of stem cell receptors and their chemical properties to “tag” and identify these cells and sort them by FACS or visualize them under a microscope followed by fluorescent tagging.

Name	Cat. No.	Comments	Size	Price
Anti-BMI1 (1-326) Rabbit pAb	AP1050	Liquid, polyclonal IgG, undiluted serum. Immunogen used was a full-length recombinant human BMI-1 protein (amino acids 1-326). Recognizes the ~44 kDa BMI protein in U2OS cells. <b>IB</b>	50 µl	€117
Anti-Nestin Rabbit pAb	ST1117	Liquid, polyclonal IgG, purified. Immunogen used was a synthetic peptide corresponding to amino acids from an internal region of human NES. Recognizes the ~220 kDa Nestin protein in SHSY-5Y cells. <b>IB, IP</b>	50 µg	€117
Anti-Nestin Mouse mAb (2C13B9)	ST1111	Liquid, monoclonal IgG, purified. Immunogen used was a GST fusion protein containing amino acids 1464-1614 of human nestin. Recognizes the ~220-240 kDa Nestin protein in U251 cells. <b>FS, IB, IC</b>	100 µl	€218
Anti-Nanog Rabbit pAb	SC1000	Liquid, polyclonal IgG, purified. Immunogen used was a synthetic peptide corresponding to amino acids within residues 1-50 of mouse Nanog. Recognizes the ~40 kDa Nanog protein in mouse myeloid and embryonic stem cells. <b>IB, IP</b>	50 µg	€130
Anti-CD117 Mouse mAb (57A5)	218150	Liquid, monoclonal IgG, purified. Immunogen used was human M07e tumor cells. Recognizes the ~150 kDa CD117 protein in human cells. <b>FC, FS, IP</b>	100 µg	€260
Anti-CD34 Mouse mAb (QBEnd/10)	OP164	Liquid, monoclonal IgG, purified. Immunogen used was detergent-solubilized vesicular suspension prepared from a perfusate of human term placenta. Recognizes CD34 selectively expressed on human lymphoid and myeloid hematopoietic progenitor cells and on vascular endothelial cells in normal tissues and benign and malignant proliferations. <b>FC, PS</b>	100 µg	€294
Anti-Pax3 Rabbit pAb	CA1010	Liquid, polyclonal IgG, undiluted serum. Immunogen used was a recombinant protein containing amino acids 1-347 of human Pax3 fused to GST. Recognizes the ~56 kDa Pax3 protein, the ~97 kDa Pax3-FHKL fusion protein, and possibly other Pax3 splice variants. <b>IB, IC</b>	50 µl	€314
Anti-Pax-5 (1-15) Rabbit pAb	PC700	Liquid, polyclonal IgG, purified. Immunogen used was a synthetic peptide (MDLEKNYPTPTSRT) corresponding to amino acids 1-15 of human Pax-5. Recognizes the ~50 kDa Pax-5 protein in Raji cell nuclear extracts. <b>ELISA, IB</b>	100 µl	€356
Anti-BMP-1 (Ab-1) Rabbit pAb	PC571	Liquid, polyclonal IgG, purified. Immunogen used was a synthetic peptide corresponding to amino acids at the N-terminus of human BMP-1. Recognizes the ~97-110 kDa BMP-1 protein in culture medium from TPA-treated fibroblasts. <b>IB</b>	50 µg	€220
Anti-BMP-2/4, C-Terminal Rabbit pAb	203640	Liquid, polyclonal IgG. Immunogen used was a synthetic peptide corresponding to the last 20 amino acids at the C-terminus of human BNP-2/4. Recognizes the ~18 kDa (reducing conditions) BMP-2 and BMP-4 proteins. <b>ELISA, IB, IP</b>	100 µg	€315
Anti-BNF1 (150-250) Rabbit pAb	CA1021	Liquid, polyclonal IgG, purified. Immunogen used was a synthetic peptide corresponding to amino acids within residues 150-250 of human BNF1. Recognizes the ~50 kDa BNF1 protein in DU145 cells. <b>IB</b>	50 µg	€153

**ELISA:** enzyme-linked immunosorbent assay; **FC:** flow cytometry; **FS:** frozen sections; **IB:** immunoblotting; **IC:** immunocytochemistry; **IP:** immunoprecipitation; **mAb:** monoclonal; **pAb:** polyclonal; **PS:** paraffin sections


# Modulators of Stem Cell Differentiation

Name	Cat. No.	Comments	Size	Price
Cardiogenol C	217460	A cell-permeable pyrimidine compound that potently induces the differentiation of embryonic stem cells into cardiomyocytes ( $EC_{50} = 100$ nM). <i>Purity: <math>\geq 95\%</math> by HPLC.</i>	5 mg	€173
Cyclopamine, <i>Veratrum californicum</i>	239803	A natural alkaloid isolated that acts as a specific Sonic Hedgehog signaling antagonist. Acts at the level of Smoothened (Smo). <i>Purity: <math>\geq 97\%</math> by HPLC.</i>	1 mg	€148
Cyclopamine-KAAD	239804	A potent analog of Cyclopamine (Cat. No. 239803) that specifically inhibits the Hedgehog (Hh) signaling with similar or lower toxicity ( $IC_{50} = 20$ nM in Shh-LIGHT2 assay; 50 nM in p2 <sup>lch</sup> -/- cells; 500 nM in SmoA1-LIGHT cells). Binds to SmoA1 and promotes its exit from the endoplasmic reticulum. Suppresses both the ShhNp-induced pathway activity and SmoA1-induced reporter activity. <i>Purity: <math>\geq 95\%</math> by TLC.</i>	100 $\mu$ g	€158
Jervine	420210	A cell-permeable steroidal alkaloid similar to cyclopamine (Cat. No. 239803) that blocks Sonic Hedgehog signaling ( $IC_{50} \sim 500 - 700$ nM in s12 cells). <i>Purity: <math>\geq 98\%</math> by TLC.</i>	1 mg	€93
Purmorphamine	540220	A cell-permeable purine compound that induces osteoblast differentiation of multipotent mesenchymal progenitor cells C3H10T1/2 ( $EC_{50} = 1$ $\mu$ M) and lineage-committed preosteoblasts MC3T3-E1. Its effect can be synergized with that of bone morphogenetic protein-4. <i>Purity: <math>\geq 98\%</math> by HPLC.</i>	5 mg	€173
Reversine	554717	A cell-permeable purine analog that acts as a dedifferentiation-inducing agent. Shown to induce mouse C2C12 myoblast cells to become multipotent mesenchymal progenitor cells in the concentration range of 1 - 10 $\mu$ M. <i>Purity: <math>\geq 95\%</math> by HPLC.</i>	5 mg	€173
SANT-1	559303	A potent antagonist of the Sonic Hedgehog signaling pathway ( $IC_{50} = 20$ nM in the Shh-LIGHT2 assay and in Ptch1 <sup>-/-</sup> cells) by binding directly to Smoothened (Smo; $K_d = 1.2$ nM). <i>Purity: <math>\geq 95\%</math> by HPLC.</i>	5 mg	€130
Stem Cell Proliferation Inhibitor	569620	A tetrapeptide (Ac-SDKP) that acts as a natural inhibitor of pluripotent hematopoietic stem cell proliferation. Protects bone marrow against chemotherapeutic agents, ionizing radiations, hyperthermia, or phototherapy-induced toxicity. <i>Purity: <math>\geq 97\%</math> by HPLC.</i>	5 mg	€159
Stem Cell Factor, Human, Recombinant, <i>E. coli</i>	569600	A hematopoietic growth factor that stimulates the growth of cells of multiple lineage. <i>Biological activity: <math>ED_{50} = 2.5 - 5.0</math> ng/ml as measured in a cell proliferation assay using a factor-dependent human erythroleukemic cell line. Purity: <math>\geq 95\%</math> by SDS-PAGE.</i>	10 $\mu$ g	€376
Stem Cell Factor, Mouse, Recombinant, <i>E. coli</i>	569610	A hematopoietic growth factor. <i>Biological activity: <math>ED_{50} = 5.0 - 10.0</math> ng/ml as measured in a cell proliferation assay using a factor-dependent human erythroleukemic cell line. Purity: <math>\geq 95\%</math> by SDS-PAGE.</i>	10 $\mu$ g	€376

## **NEW** Kits for your Proteomics Research

### ProteoExtract® Phosphopeptide Enrichment SCIMAC Kit

The ProteoExtract® Phosphopeptide Enrichment SCIMAC Kit is a useful tool for enrichment of phosphorylated peptides from complex samples by combination of strong cation exchange chromatography (SCX) and immobilized metal ion affinity chromatography (IMAC). The identification of phosphorylation sites is accomplished by mass spectrometry. Captured and eluted phosphopeptide fractions are ready for MALDI- and ESI- mass spectrometry analysis.



The combination of SCX and IMAC exhibits high selectivity for phosphopeptides by reducing non-specific binding of peptides from complex mixtures. A complex peptide mixture derived from a tryptic digest of porcine liver extract was spiked with  $\alpha$ -casein and two synthetic phosphopeptides. The samples were subsequently processed using (A) an iron oxide-based IMAC material alone or (B) the combination of SCX with zirconium-based IMAC particles. Mass spectrometry analysis was performed using ESI-LC/MS equipment operated in positive mode.

Cat. No. 539723

1 kit


€206



## NEW Kits for your Proteomics Research (continued...)

### ProteoExtract® Phosphopeptide Enrichment TiO<sub>2</sub> Kit

The ProteoExtract® Phosphopeptide TiO<sub>2</sub> Enrichment Kit is designed for enrichment of phosphorylated peptides from complex samples by a highly selective titanium oxide solid phase. It enhances the ability to routinely identify and characterize large numbers of phosphorylated species within complex protein mixtures taking advantage of a novel titanium dioxide material. Captured and eluted phosphopeptide fractions are ready for MALDI- and ESI- mass spectrometry analysis.



The activity of titanium dioxide allows for selective and sensitive phosphopeptide enrichment with low background from complex mixtures. A complex peptide mixture derived from a tryptic digest of porcine liver extract was spiked with  $\alpha$ -casein and two synthetic phosphopeptides. The samples were subsequently processed using the ProteoExtract® Phosphopeptide Enrichment Kit TiO<sub>2</sub> Kit. Mass spectrometry analysis was performed using ESI-LC/MS equipment operated in positive mode. (A): unprocessed sample and (B): Phosphopeptides recovered using the ProteoExtract® Phosphopeptide Enrichment Kit TiO<sub>2</sub> Kit.

Cat. No. 539722


1 kit

€214

### InnoZyme™ Calpain1/2 Activity Assay Kit

Assay range: 63–1000 ng/ml

A highly sensitive and specific assay for measuring calpain 1 and 2 activity in cell lysates or tissue extracts and for screening enzyme calpain inhibitors. The substrate used in this assay (DQABCYL)-TPLKSPPPSPR-(EDANS) is based on the finding that amino acid preferences for calpain recognition/cleavage extend to 11 positions around the scissile amide bond. Cleavage of the K-S bond relieves internal quenching resulting in increase in fluorescence (*Exc. Max.* 320 nm and *Em. Max.* 480 ± 20 nm).



A: Activity of Calpain 1, Human Erythrocytes (Cat. No. 208713)

B: Activities of Calpain 2, Porcine Kidney (Cat. No. 208715) and Calpain 2, Rat, Recombinant, High Purity, *E. coli* (Cat. No. 208718)

Cat. No. CBA054

1 kit

€324

## Transdermal Hormone Delivery Peptide, TD-1

(H-ACSSSPSKHCG-OH, Cyclic)

A highly hydrophilic [Cys-Cys] cyclic 11-mer peptide that facilitates transdermal protein drug delivery by creating a transient opening in the skin barrier. Topical coadministration of TD-1 has been shown to enable insulin and human growth hormone to reach systemic circulation in rats *in vivo*. Purity:  $\geq 97\%$  by HPLC. M.W. 1061.2

Cat. No. 616365

5 mg


€172

## NEW Histone Deacetylase Inhibitors

### Histone Deacetylase Inhibitor IV

(N<sup>1</sup>-(2-Aminophenyl)-N<sup>7</sup>-phenylheptanediamide)

A cell-permeable, specific inhibitor of HDAC. Shown to reverse the silencing of *FXN* transcription in FRDA (Friedreich's ataxia) cells due to hypoacetylation of histones H3 and H4 by increasing acetylation at H3K14, H4K5 and H4K12, without significant changes in acetylation at H3K9, H4K8 and H4K16. Purity:  $\geq 97\%$  by HPLC. M.W. 325.4



Cat. No. 382170

10 mg


€172

Ref.: Herman, D., et al. 2006. *Nat. Chem. Biol.* 2, 551.

### SIRT1 Inhibitor III

(6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, racemic)

A cell-permeable, potent, and highly selective inhibitor of SIRT1 ( $IC_{50}$  = 98 nM). Inhibits other sirtuin family deacetylases only at much higher concentrations ( $IC_{50}$  = 19.6 and 48.7  $\mu$ M for SIRT2 and SIRT3, respectively). Purity:  $\geq 95\%$  by HPLC. M.W. 248.7



Cat. No. 566322

5 mg

€167

Ref.: Solomon, J.M., et al. 2006. *Mol. Cell. Biol.* 26, 28; Napper, A.D., et al. 2005. *J. Med. Chem.* 48, 8045.

### SIRT1/2 Inhibitor IV, Cambinol

(NSC-112546)


A cell-permeable inhibitor of NAD-dependent deacetylase activity of hSIRT1 and hSIRT2 ( $IC_{50}$  = 56  $\mu$ M and 59  $\mu$ M, respectively) in a substrate-, but not NAD-, competitive manner. It inhibits SIRT5 deacetylase activity only at much higher concentrations ( $IC_{50}$  > 300  $\mu$ M). Purity:  $\geq 95\%$  by HPLC. M.W. 360.4

Cat. No. 566323

5 mg

€131

Ref.: Heltweg, B., et al. 2006. *Cancer Res.* 66, 4368.



Prices and availability are subject to change. ©Copyright 2007 EMD Chemicals, an affiliate of Merck KGaA, Darmstadt, Germany. All rights reserved. Each product is sold with a limited warranty which is provided with each purchase. Each product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes nor is it intended for human use. EMD Chemicals products may not be resold, modified for resale, or used to manufacture commercial products without written approval of EMD Chemicals. Calbiochem®, GeneJuice®, His•Tag®, and Novagen® are registered trademarks of EMD Chemicals Inc. in the United States and in certain other jurisdictions. InhibitorSelect™, InnoZyme™, InSolution™, Interactive Pathways™, K-LISA™, PhosphoDetect™, and S•Tag™ are trademarks of EMD Chemicals Inc. ProteoExtract® is a registered trademark of Merck KGaA, Darmstadt, Germany.



Calbiochem®

## New Research Tools for Signal Transduction and Life Science Research

Highlighting new research reagents and kits for various disease pathways research.

Call us or visit our website:  
[www.calbiochem.com/newtools](http://www.calbiochem.com/newtools)

Novagen®

Nourish your cells with  
**100% GeneJuice®**  
 Transfection Reagent!

**GeneJuice** is optimized for maximal transfection efficiency and ease of use. With minimal cytotoxicity, GeneJuice is the transfection reagent of choice for happier and **healthier cells**.

- Provides maximal transfection efficiencies
- Optimized for stable and transient transfections
- Minimal cellular toxicity
- Compatible with serum-containing and serum-free media
- Simple protocol - no need for media changes

Visit our Transfection Reagent Resource web page for protocols, cell-line specific transfection conditions, and links to citations.

[www.novagen.com/transfection](http://www.novagen.com/transfection)

Use 100%  
**GeneJuice®**  
 Transfection Reagent



Keep your  
 cells healthy

For more information or to order  
Calbiochem products, contact  
Merck Chemicals Ltd.  
Boulevard Industrial Park  
Padge Road, Beeston  
Nottingham NG9 2JR  
UK

**France**  
Merck Chemicals Ltd.

*Service Clients*

Téléphone 0800 699 620 (numéro vert)  
Fax 0800 348 630 (numéro vert)  
E-mail [customer.service@merckbio.eu](mailto:customer.service@merckbio.eu)

*Service Technique*

Téléphone 0800 126 461 (numéro vert)  
E-mail [techservice@merckbio.eu](mailto:techservice@merckbio.eu)

*Visit our website*  
[www.merckbio.eu](http://www.merckbio.eu)

**Germany**  
Merck Chemicals Ltd.

*Orders*

Freecall 0800 6931 000  
Tel 06196 564952  
Freefax 0800 6236 100  
E-mail [customer.service@merckbio.eu](mailto:customer.service@merckbio.eu)

*Technical Support*

Freecall 0800 100 3496  
E-mail [techservice@merckbio.eu](mailto:techservice@merckbio.eu)

*Visit our website*  
[www.merckbio.eu](http://www.merckbio.eu)

**Republic of Ireland**  
Merck Chemicals Ltd.

*Orders*

Toll free 1800 409 445  
Tel +44 115 943 0840  
Fax +44 115 943 0951  
E-mail [customer.service@merckbio.eu](mailto:customer.service@merckbio.eu)

*Technical Support*

Toll free 1800 409 445  
E-mail [techservice@merckbio.eu](mailto:techservice@merckbio.eu)

*Visit our website*  
[www.merckbio.eu](http://www.merckbio.eu)

**Other Countries**  
Merck Chemicals Ltd.

*Orders*

Tel +44 (0)115 943 0840  
Fax +44 (0)115 943 0951  
E-mail [customer.service@merckbio.eu](mailto:customer.service@merckbio.eu)

*Technical Support*

Tel +44 (0)115 943 0840  
E-mail [techservice@merckbio.eu](mailto:techservice@merckbio.eu)

*Visit our website*  
[www.merckbio.eu](http://www.merckbio.eu)



10001813  
Biologics 33.2 2007 EUR